10% owner Adar1 Capital acquired 468,551 shares in 3 transactions at $1.54–$1.60, raising stake to 800,000 shares (+141.4%)
Adar1 Capital Management, LLC, a 10% shareholder, executed 3 separate purchases totaling 468,551 shares for $721,547.89 at an average price of $1.54. This acquisition increased the insider's holdings by 141.4%, from 331,449 to 800,000 shares. The transactions occurred at prices substantially below the current market price of $1.73, and well below the 52-week high of $7.98, reflecting a 78.3% decline from that peak. InMed Pharmaceuticals is currently unprofitable (latest quarter net income: $-2,966,336.00; full-year: negative) with minimal quarterly revenue of $820,188.00, placing this small-cap position in a highly speculative context. The insider's cross-ticker track record shows 17 prior buys with a 100% 90-day win rate and +10.6% average 90-day return, though this ticker-specific history is unmeasurable in the FACTS provided, limiting confidence in predicting outcome.